Genovis AB sues US company for patent infringement

The Board of Directors of Genovis has announced that it has filed a lawsuit
against Promega Corporation (“Promega”) for patent infringement regarding one of
Promega’s products. The lawsuit includes an injunction to prevent Promega from
producing, using, selling or offering for sale the infringing product, as well
as damages. The suit was filed in the United State District Court of Delaware.
Genovis develops, produces and markets innovative technologies that facilitate
and enable development of new treatment methods, as well as diagnostics for the
pharmaceutical industry. The suit relates to Promega’s new product IdeS
Protease, which Genovis believes infringes US Patent No. 7.666.582 for which
Genovis has an exclusive global license that expires in 2022 and covers Genovis’
product FabRICATOR®. Genovis has not provided any sublicense to Promega.

“Pursuing legal action is time consuming, but at the same time it is important
for Genovis to protect the intellectual property that belongs to the company and
its shareholders. FabRICATOR® is the first product Genovis launched and has been
sold with good growth in the U.S. market since 2009. The product has also helped
to create markets for our other product launches to the world’s leading
pharmaceutical companies. Genovis has insurance that covers most of the cost of
the suit and I would like to point out that the patent infringement only applies
to the U.S. market,” says Sarah Fredriksson, CEO of Genovis.

Genovis’ customers include pharmaceutical and biotech companies, academia and
regulatory authorities, including the FDA. They all use FabRICATOR to
characterize antibody-based drugs.  Modern biological pharmaceuticals against
diseases such as cancer are frequently made of antibody molecules that require
advanced technology to characterize and analyze them. Analysis is an important
cornerstone prior to registration with regulatory authorities, as well as for
quality control during production of the approved drug. FabRICATOR is extremely
fast and accurate, which enables customers to use a new analytical technique
that provides reliable, more easily interpreted results. Customers also save
time and lower their analysis costs.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ OMX First North, and Consensus is Certified
Adviser for the Company, t: 46 (0)31-745 50 00